Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
30 mai 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today...
Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
28 mai 2024 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
Evkeeza is een eerste klasse geneesmiddel dat wordt aanbevolen voor vergoeding door het Nederlands Agentschap voor Gezondheidstechnologie voor de behandeling van HoFH bij patiënten ≥ 5 jaar oud ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 mai 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
07 mai 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
02 mai 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million,...
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
30 avr. 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to...
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
30 avr. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies...
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
25 avr. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 avr. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
15 avr. 2024 07h00 HE
|
Ultragenyx Pharmaceutical Inc.
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in...